Edition:
India

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

16.98USD
11 Dec 2017
Change (% chg)

$1.17 (+7.40%)
Prev Close
$15.81
Open
$16.04
Day's High
$17.28
Day's Low
$16.04
Volume
40,480
Avg. Vol
17,848
52-wk High
$21.01
52-wk Low
$12.75

Select another date:

Fri, Nov 10 2017

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

BRIEF-Mersana Therapeutics increases size of board and appoints Lawrence Alleva as class III director‍​

* Mersana Therapeutics Inc - Increased size of the board from six to seven directors and appointed Lawrence M. Alleva to serve as a class III director‍​ Source text: (http://bit.ly/2j4r2t3) Further company coverage:

BRIEF-Mersana Q2 loss per share $6.33

* Mersana announces second quarter 2017 financial results and provides business updates

BRIEF-Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing

* Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing Source text for Eikon: Further company coverage:

BRIEF-Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017

* Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing Source text (http://bit.ly/2uTwTCc) Further company coverage:

BRIEF-Mersana Therapeutics announces pricing of initial public offering

* Mersana Therapeutics announces pricing of initial public offering

BRIEF-Mersana Therapeutics sees IPO of 5 mln shares priced between $14 and $16

* Mersana Therapeutics Inc sees IPO of 5 million shares priced between between $14.00 and $16.00 - SEC filing Source text for Eikon: Further company coverage:

Select another date: